Equities Analysts Set Expectations for TCRX Q2 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Stock analysts at HC Wainwright lifted their Q2 2025 EPS estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.31) EPS.

Several other research analysts have also recently weighed in on TCRX. Needham & Company LLC reissued a “buy” rating and set a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Barclays lowered their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Wedbush reissued an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Finally, Morgan Stanley restated an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, TScan Therapeutics has a consensus rating of “Buy” and an average target price of $8.50.

TScan Therapeutics Trading Down 6.9%

Shares of TCRX stock opened at $1.29 on Monday. The company’s 50-day moving average price is $1.49 and its 200-day moving average price is $2.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a market cap of $72.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.06. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.62 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Deutsche Bank AG increased its stake in TScan Therapeutics by 149.4% during the first quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after purchasing an additional 31,481 shares during the period. Letko Brosseau & Associates Inc. increased its stake in TScan Therapeutics by 113.0% during the first quarter. Letko Brosseau & Associates Inc. now owns 77,100 shares of the company’s stock worth $106,000 after purchasing an additional 40,900 shares during the period. Wellington Management Group LLP increased its stake in TScan Therapeutics by 5.2% during the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock worth $404,000 after purchasing an additional 6,550 shares during the period. Heck Capital Advisors LLC purchased a new stake in TScan Therapeutics during the fourth quarter worth about $61,000. Finally, Woodline Partners LP increased its stake in TScan Therapeutics by 6.7% during the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after purchasing an additional 7,282 shares during the period. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.